IQ Capital specialises in backing IP-rich technology businesses with a track record of stable growth.
The round was led by Join Capital with participation from IQ Capital, Northern Gritstone, Seraphim, Episode 1 and Schauenburg Ventures to fund global growth and product development.
"Opteran has built the AI technology required to transform autonomous machines beyond today’s limited use in restricted scenarios to enable more widespread adoption,"
Evolution Equity Partners led the Series B funding to accelerate product development and international expansion.
"We invest in founders with disruptive cybersecurity offerings that are reimagining how businesses approach the increasing depth and breadth of cyber threats. CybSafe’s disruptive approach tackles a complex problem with a simple solution. They design their products with the user in mind, ensuring they are tackling the cause rather than simply treating the symptoms of cyber risk. CybSafe goes far beyond traditional compliance driven approaches to security awareness, and instead focuses on delivering a genuine reduction in human cyber risk."
The Series B round was led by New Science Ventures to support international growth and manufacturing expansion.
"Our increasing desire for continually improving electronic device performance paired with the absolute necessity to reduce our power requirements, and hence carbon footprints, demands new technology solutions – next generation materials will be at the heart of this. At Paragraf we are proud to be leading the way, bringing the first 2D material, graphene, into the electronic product supply chain, through our first products, allowing its transformational, game changing properties and benefits to be harnessed."
The pre-seed round was co-led by IQ Capital and Ahren Innovation Capital to support team expansion and technology validation.
"Our ability to take a sample from someone with an unknown infection and answer the open question 'what do they have?' within a minute is a gamechanger for infection diagnosis and treatment. We’ll start with respiratory viruses and expand from there. In parallel, we’ll be simplifying the workflow to move the test from the lab to point of care, which will represent a step change in the availability and cost of infectious disease diagnostics worldwide."
Seedcamp led the oversubscribed round alongside existing investors IQ Capital and Playfair Capital.
"Our studio has naturally wanted to transition over the years into being worldbuilding-led so it could not be better timing seeing a new audience emerge that is looking for immersive game-like experiences where they own parts of the universes they love. At Cauldron we have a history of working in markets where we know our art and emotive storytelling can have a dramatic impact and we are seeing the rising base of Web3 players yearning for more."
